|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412 (abst) 显示文摘 | Ryan CW Goldman BH Lara PN | 2006 | Proc Am Soc Clin Oncol2006，24，： | 1 |
| 2 | Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group 显示文摘 | Ryan CW Goldman BH Lara PN Jr | 2007 | J Clin Onco12007，25，22： | 1 |
| 3 | Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase Ⅱ study of the Southwest Oncology Group 显示文摘 | Ryan CW Goldman BH Lara PNJr | 2007 | J Clin Oncol2007，25，22： | 1 |
| 4 | Cetuximab plus cisplatin, irinotecan , and thoracic radiotherapy as de- finitive treatment for locally advanced, unresectable esoph?ageal cancer: a phase - II study of the SWOG (S0414)显示文摘 | Tomblyn MB Goldman BH Thomas CR | 2012 | J Thorac Oncol2012，7，5： | 1 |
| 5 | Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase - II study of the SWOG (S0414) 显示文摘 | Tomblyn MB Goldman BH Thomas CR Jr | 2012 | J Thorac Oncol2012，7，5： | 1 |
| 6 | Dual blockade of epidermal growth factor receptor (EGFR) and insu- lin-like growth factor receptor-1 (IGF-1R) signaling in metastatic pancreatic cancer: Phase I/randomized phase Ⅱ trial of gemcit- abine, erlotinib, and cixutumumab versus gemcitabine plus erlo- tinib (SWOG-0727) 显示文摘 | PHILIP PA GOLDMAN BH RAMANATHAN RK | 2012 | J Clin Oncol2012，，： | 1 |
| 7 | Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treat- ment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414) 显示文摘 | Tomblyn MB Goldman BH Thomas CR Jr | 2012 | J Thorac Oncol2012，7，5： | 1 |
| 8 | Sorafenib plus interferon-α2b(IFN) as first-line therapy for advanced renal cell carcinoma (RCC) : SWOG 0412 显示文摘 | Ryan CW Goldman BH Lara PN | 2006 | J Clin Oncol2006，24，18： | 1 |
| 9 | Sorafenib with inter- feron alfa-2b as first-line treatment of advanced renal carcinoma: a phase 11 stud~' of the Southwest Oncology Group 显示文摘 | Ryan CW Goldman BH Lara PN Jr | 2007 | J Clin Oncol2007，25，22： | 1 |
| 10 | Sorafenib with interferonalfa -2b as first - line teratment of advanced renal carcinoma aphase II study of the Southwest Onclogy Group 显示文摘 | Ryan CW Goldman BH Lara PJ | 2007 | J Clin Oncol2007，25，22： | 1 |
| 11 | Collagenase plaque digestion for facilitating guide wire erossing in chronic total occlusions 显示文摘 | Strauss BH Goldman L Qiang B | 2003 | Circulation2003，108，10： | 1 |
| 12 | Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase 17 study of the Southwest Oncology Group显示文摘 | Ryan CW Goldman BH Lara PNJr | 2007 | J Clin Oncol2007，25，22： | 1 |
| 13 | A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517显示文摘 | Kirschbaum MH Goldman BH ZainJM | 2012 | Leuk Lymphoma2012，53，2： | 1 |
| 14 | Sorafenibplus inter- feron- α 2b(IFN) as first-line therapy for advanced renal cell carcinoma (RCC):SWOG 0412显示文摘 | Ryan CW Goldman BH Lara PN | 2006 | J Clin Oncol2006，24，18： | 1 |
| 15 | Sorafenib plus interferon- α2b(IFN) as first - line therapy for advanced renal cell carcinoma(ROE): SWOG 0412 显示文摘 | Ryan C'W Goldman BH Lara PN | 2006 | J Clin Oncol2006，24，18： | 1 |
| 16 | Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group 显示文摘 | Ryan CW Goldman BH Lara PN Jr | 2007 | J Clin Oncol2007，25，22： | 1 |
| 17 | Collagenase plaque digestion for facilitating guidewire crossing in chronic total ocdusions 显示文摘 | Strauss BH Goldman L Qiang B | 2003 | Circulation2003，108，： | 1 |
| 18 | Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG0412 (abst) 显示文摘 | Ryan CW Goldman BH Lara PN | 2006 | Proc Am Soc Clin Oncol2006，24，： | 1 |
| 19 | Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally ad- vanced, unresectable esophageal cancer: a phase-II study of the SWOG(S0414) 显示文摘 | Tomblyn MB Goldman BH | 2012 | Thorac 0ncol2012，7，5： | 1 |
| 20 | Sorafenib plus interferonalpha2b(IFN)as first-line therapy for advanced renal cell carcinoma,SWOG 0412显示文摘 | Ryan CW Goldman BH Lara PN Jr | 2007 | J Clin Oncol2007，25，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员